Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are evaluating DS-3939a, an antibody drug conjugate ADC, for safety, tolerability, and effectiveness in adults with advanced solid tumors, including locally advanced, metastatic, or unresectable cancers. This first-in-human phase 12 clinical trial is divided into two parts dose escalation and dose expansion, focusing on participants with measurable disease and good performance status. Participants will receive DS-3939a as an intravenous infusion every 3 weeks on Day 1 of each 21-day cycle. The study includes a dose escalation part where dosing starts at 1 mgkg and a dose expansion part with multiple cohorts targeting various advanced solid tumors. Treatment continues with monitoring for dose-limiting toxicities and response rates over approximately 31 months. During the study, participants will undergo assessments including tumor biopsies, echocardiograms, and laboratory tests to monitor organ function and immune response. Researchers will track adverse events, tumor response, and pharmacokinetics through scheduled visits and sample collections. The study may last up to nearly 5 years, including treatment and follow-up periods, to evaluate long-term safety and efficacy outcomes.
Actively Recruiting
Researchers are studying treatments for participants with locally advanced or metastatic urothelial carcinoma lamUC who have progressed during or after prior therapy with enfortumab vedotin EV plus pembrolizumab. This global, multicenter, randomized, open-label Phase 23 trial aims to evaluate the combination of Datopotamab Deruxtecan Dato-DXd plus carboplatin or cisplatin compared to gemcitabine plus carboplatin or cisplatin. The initial Phase 2 part will assess preliminary efficacy and safety to determine the recommended Phase 3 dose RP3D, with the Phase 3 part starting based on these findings.